Mark L Chicote
Overview
Explore the profile of Mark L Chicote including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimball A, Bourassa J, Chicote M, Gerweck A, Dichtel L, Miller K
Arch Womens Ment Health
. 2024 Nov;
PMID: 39601877
Purpose: Menstrually related mood disorder (MRMD) is marked by severe affective symptoms in the late luteal phase of the menstrual cycle. We hypothesized that women with MRMD experience relative neuroactive...
2.
Dichtel L, Tabari A, Mercaldo N, Corey K, Husseini J, Osganian S, et al.
J Clin Exp Hepatol
. 2023 Sep;
13(5):760-766.
PMID: 37693260
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease worldwide. There are limited biomarkers that can detect progression from simple steatosis to nonalcoholic steatohepatitis (NASH)....
3.
Dichtel L, Corey K, Haines M, Chicote M, Lee H, Kimball A, et al.
J Clin Endocrinol Metab
. 2023 Jun;
108(12):e1542-e1550.
PMID: 37379033
Context: Overweight and obesity are associated with relative growth hormone (GH) deficiency, which has been implicated in the development of nonalcoholic fatty liver disease (NAFLD). NAFLD is a progressive disease...
4.
Osganian S, Subudhi S, Masia R, Drescher H, Bartsch L, Chicote M, et al.
Growth Horm IGF Res
. 2022 Jul;
65:101482.
PMID: 35780715
Objective: The GH and IGF-1 axis is a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) given its lipolytic, anti-inflammatory and anti-fibrotic properties. IGF-1 receptor (IGF-1R) and GH receptor...
5.
Dichtel L, Corey K, Haines M, Chicote M, Kimball A, Colling C, et al.
J Clin Endocrinol Metab
. 2022 Jul;
107(9):e3624-e3632.
PMID: 35779256
Context: Obesity is a state of relative growth hormone (GH) deficiency, and GH has been identified as a candidate disease-modifying target in nonalcoholic fatty liver disease (NAFLD) because of its...